Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
HRTX 
Heron Therapeuti (HRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: HRTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.79% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 231.04M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 3 | Beta 1.28 | 52 Weeks Range 1.00 - 2.68 | Updated Date 01/8/2026 |
52 Weeks Range 1.00 - 2.68 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.76% | Operating Margin (TTM) -10.71% |
Management Effectiveness
Return on Assets (TTM) 0.43% | Return on Equity (TTM) -2408.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 316520276 | Price to Sales(TTM) 1.49 |
Enterprise Value 316520276 | Price to Sales(TTM) 1.49 | ||
Enterprise Value to Revenue 2.04 | Enterprise Value to EBITDA 39.89 | Shares Outstanding 183362522 | Shares Floating 132121865 |
Shares Outstanding 183362522 | Shares Floating 132121865 | ||
Percent Insiders 0.65 | Percent Institutions 84.38 |
Upturn AI SWOT
Heron Therapeuti
Company Overview
History and Background
Heron Therapeutics, Inc. (Nasdaq: HRBN) was founded in 2001. It is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer patients. Key milestones include the development and FDA approval of their oncology products, as well as strategic collaborations and pipeline advancements.
Core Business Areas
- Oncology Therapeutics: Development and commercialization of novel drug candidates and approved therapies targeting various forms of cancer. This includes treatments for hematologic malignancies and solid tumors.
Leadership and Structure
Heron Therapeutics is led by a seasoned management team with expertise in biopharmaceuticals, oncology, and commercial operations. The company operates as a standard C-corporation with functional departments overseeing research and development, clinical operations, regulatory affairs, manufacturing, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Description: Heron Therapeutics has developed and commercialized antiemetic therapies to manage chemotherapy-induced nausea and vomiting (CINV). CINVANTI (aprepitant) is a notable product in this area. Competitors include Merck (Emend), Eisai, and other pharmaceutical companies with antiemetic drugs.
- Name: CINV treatments (e.g., CINVANTI, zuplenz)
- Revenue: [object Object],[object Object],[object Object]
- Description: Heron is also developing therapies for acute postoperative pain, aiming to reduce opioid use. Their product candidates in this area target a significant unmet need. Competitors include companies developing non-opioid pain management solutions and other pain management drug developers.
- Name: Acute Postoperative Pain Management
- Revenue:
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology sector, is characterized by rapid innovation, high R&D costs, and rigorous regulatory oversight. The market for cancer therapies is substantial and growing due to an aging population and advancements in understanding cancer biology. The market for antiemetics is also significant, driven by the widespread use of chemotherapy.
Positioning
Heron Therapeutics is positioned as a specialized biopharmaceutical company focused on addressing unmet needs in oncology supportive care and treatment. Their strategy emphasizes developing differentiated products that offer significant clinical benefits to patients and healthcare providers. Competitive advantages lie in their specific product formulations and therapeutic focus.
Total Addressable Market (TAM)
The TAM for oncology supportive care, including antiemetics and pain management, is substantial and continues to grow. While specific TAM figures vary, the global market for oncology drugs alone is projected to reach hundreds of billions of dollars. Heron Therapeutics aims to capture a significant share of the niche markets they target with their specialized therapies.
Upturn SWOT Analysis
Strengths
- Experienced management team with biopharmaceutical expertise.
- Portfolio of approved oncology supportive care products.
- Potential for pipeline products to address unmet medical needs.
- Focus on differentiated drug formulations.
Weaknesses
- Dependence on a limited number of key products.
- Significant R&D investment required for pipeline development.
- Potential for competition from larger pharmaceutical companies.
- Need for continued commercialization efforts and market penetration.
Opportunities
- Expanding the indications for existing products.
- Advancing the pipeline for novel oncology treatments.
- Strategic partnerships and collaborations.
- Growing global demand for advanced cancer therapies.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and approvals.
- Pricing pressures and reimbursement challenges.
- Emergence of new competing therapies.
- Patent expirations and generic competition.
Competitors and Market Share
Key Competitors
- Merck & Co., Inc. (MRK)
- Eisai Co., Ltd. (ESAY - ADR)
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
Heron Therapeutics competes in a dynamic market with established pharmaceutical giants and emerging biotechs. Its advantages lie in its specialized focus on oncology supportive care and potentially differentiated product profiles. However, it faces challenges from the extensive resources and established market presence of larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Heron Therapeutics has demonstrated historical growth in revenue from its commercialized products, driven by market adoption and expanding sales efforts. However, overall financial growth has been impacted by significant investments in its development pipeline.
Future Projections: Future growth is anticipated to be driven by the successful development and commercialization of its pipeline candidates, particularly in oncology. Analyst projections generally forecast revenue growth contingent on pipeline success and market penetration of new therapies. However, profitability remains a key milestone to achieve.
Recent Initiatives: Recent initiatives likely include advancing late-stage clinical trials for pipeline assets, optimizing manufacturing processes, expanding commercial infrastructure, and potentially pursuing strategic partnerships or licensing agreements to enhance its portfolio and market reach.
Summary
Heron Therapeutics is a biopharmaceutical company focused on oncology supportive care, with established antiemetic products contributing to revenue. While it has demonstrated commercial success in its niche, significant R&D investments continue to result in net losses. Key to its future is the successful development and commercialization of its pipeline candidates, navigating regulatory hurdles, and managing competition in the highly dynamic oncology market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Heron Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share data is illustrative and may vary depending on the specific market segment and reporting period.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heron Therapeuti
Exchange NASDAQ | Headquaters Cary, NC, United States | ||
IPO Launch date 1987-08-26 | CEO & Director Mr. Craig Alexander Collard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.herontx.com |
Full time employees 122 | Website https://www.herontx.com | ||
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.